Intellia TherapeuticsNTLA

Intellia reported its second quarter financial results, which show a business in transition from a research lab to a commercial drugmaker. The company is currently working toward its first-ever regulatory approval for a CRISPR therapy, a tool that allows scientists to precisely edit DNA to treat genetic diseases.

Because the company does not yet have a drug on the market, it still relies on cash reserves and partnerships to fund its work. The focus for long-term owners remains on the 2027 launch timeline and the company's ability to manage its cash, which it previously stated should last into 2028. This quarter confirms that the business is staying on that track as it builds out the manufacturing and sales teams needed to support its first approved medicine.

Source: GlobeNewsWire

The company is moving toward becoming a commercial business, with plans to submit its first drug for FDA approval in the second half of 2026. This treatment, called lonvo-z, targets a rare swelling disorder and could launch in the U.S. by early 2027. This would be a major milestone, as it would be the first time a CRISPR therapy that edits genes directly inside a patient's body reaches the market.

Financially, the company lost about 80 cents per share on roughly $10 million in revenue, which was in line with what analysts expected. With $628 million in cash, the company has enough funding to keep operating into 2028. This gives it a clear path to get its first drugs through the final stages of testing and onto the market without needing to raise more money immediately.

See the full quarter, and how our tracked metrics did

Source: 8-K filing

Key highlights

• Path to commercial launch: Management expects the FDA to accept the filing for lonvo z in the second half of 2026, which would keep the company on schedule for a first commercial launch in the first half of 2027. This is the critical step for moving from a research lab to a revenue producing business.
• Strong attack reduction maintained: Phase 3 data for lonvo z showed an 87% reduction in disease attacks compared to a placebo, and 62% of patients were completely free of attacks and therapy for six months. These results match earlier trials and suggest the treatment could permanently fix the root cause of the disorder.
• Trial enrollment targets set: The company expects to finish enrolling patients for its polyneuropathy study in the second half of 2026. This follows the reinitiation of Phase 3 trials in the second quarter after the company completed a genomic analysis of 600 patient samples to better understand safety results.
• Cash runway extended: The company ended the quarter with $628.4 million in cash, which is enough to fund operations at least into 2028. This total was boosted by $195 million in net proceeds from a stock sale in April, giving the business a cushion through its first anticipated drug launch.
• Operating expenses shifting: General and administrative spending rose to $37.8 million from $27.2 million a year ago as the company builds out the sales and legal teams needed for its first commercial product. This shift is expected as the business prepares to transition from testing drugs to selling them.

Our take: A productive quarter that moves the company closer to its first commercial drug. The 87% reduction in disease attacks is a major win that validates the gene editing approach. With enough cash to last into 2028, the company has successfully cleared the path for its 2027 launch goal.